An international research forum, held online
The 2027 Forum on Cancer Adaptation, Plasticity, and Therapeutic Vulnerability
Adaptation as the Target: From Resistance Mechanisms to Therapeutic Exploitation
- Dates
- 10–12 March 2027
- Days
- Wednesday to Friday
- Format
- Virtual
About the forum
Tumors are not static targets. Under therapeutic pressure, cancer cells change state, rewire metabolism, evade immune recognition, enter dormancy and switch lineage. These responses are the main reason that many initially effective treatments fail.
This forum brings together investigators in cancer biology, immunology, pharmacology, computational science, clinical oncology and regulatory science to examine adaptation as a biological process that can be measured, modeled and targeted, rather than only as an obstacle to be overcome.
The programme is organized around eight scientific themes, from mechanisms of immune escape through to adaptive trial design and the pathways by which new approaches reach patients in the United States.
Scientific themes
Eight sessions across three days. Detailed programme and speakers will be published as they are confirmed.
Immunotherapy resistance and adaptive immune escape
How tumors and their immune context change under checkpoint blockade and cellular therapies, and what determines durable response.
Tumor microenvironment and metabolism as adaptive states
Stromal, vascular and metabolic conditions that shape cell state and drug sensitivity.
Plasticity, lineage switching, and dormancy
Reversible and irreversible state transitions, persister cells, and the biology of residual disease.
Therapeutic vulnerability and synthetic lethality
Dependencies created by adaptation and the rational design of combinations that exploit them.
Adaptive therapy and treatment scheduling
Evolutionary principles applied to dosing, sequencing and the control of resistant populations.
Computational and AI modeling of adaptation
Mathematical, mechanistic and machine-learning approaches to predicting tumor evolution, with attention to validation.
Biomarkers and liquid biopsy for resistance monitoring
Circulating markers and longitudinal assays for detecting emerging resistance and guiding decisions.
Adaptive clinical trial design and US regulatory and access pathways
Trial architectures that respond to accumulating data, and the regulatory frameworks that govern them.
Format and principles
The forum is held entirely online so that researchers and clinicians can take part regardless of location. It is designed for scholarly exchange, with time set aside for discussion in every session.
Open scientific exchange
Sessions are structured around evidence, methods and unresolved questions, with extended discussion periods.
Editorial independence
Programme content is determined by the scientific committee. Any support will be disclosed and will not influence the programme.
Disclosure of interests
Speakers and organizers will declare relevant financial and professional relationships.
Dates and scheduling
| Forum | Wednesday 10 to Friday 12 March 2027 |
|---|---|
| Call for abstracts | To be announced |
| Programme publication | To be announced |
| Daily session times and time zone | To be announced |
Dates marked “to be announced” will be published on this site.
Scientific committee
The scientific committee and participating institutions will be listed here once confirmed. Members are responsible for the programme, abstract review and session chairing.